ICON

inVentiv Health buys i3 divisions, Campbell Alliance, allowing it to compete with CRO industry’s big players

Monday, January 31, 2011 08:00 AM

Ingenix, a UnitedHealth Group subsidiary that provides health care information to the managed care and drug development sectors, is selling off its clinical trial management and contract research services. Those holdings include i3 Research, i3 Statprobe and i3 Pharma Resourcing. 

More... »

Fortune ranking of fastest-growing companies illustrates the cyclical performance of CRO sector

Tuesday, September 14, 2010 07:53 AM

Fortune’s recent release of its 2010 list of 100 fastest-growing companies illustrates how sectors that perform in cycles, such as CROs, can either benefit or lose out when measured by a snapshot in time.

More... »

ICON Earnings Flat in Q1

Tuesday, April 27, 2010 01:53 PM

Dublin -based contract research organization ICON reported first quarter net revenues of $219 million, down slightly from $219.8 million in the same period last year.  Income from operations was $22.2 million, or $0.37 per share on a diluted basis, compared with $20.9 million, or $0.35 per share last year.

More... »

ICON Opens Office in Philippines

Tuesday, April 6, 2010 06:59 AM

Dublin, Ireland-based contract research organization (CRO) ICON opened an office in Manila, Philippines, to support the company’s growth in Asia-Pacific.

More... »

ICON Income Up 17%, Revenues Hold Steady

Tuesday, March 2, 2010 12:04 PM

Year-end revenues for Dublin-based CRO ICON increased 3% in 2009 to $888 million. Fourth quarter revenues also increased 3% to $227.4 million compared with $220.1 million for the same period last year.

More... »

Lindevall Returns as CEO of Encorium

Friday, January 15, 2010 06:44 AM

CEO musical chairs continues at Wayne, Pa.-based contract research organization (CRO) Encorium . The company has reappointed Dr. Kai Lindevall as CEO, replacing David Ginsberg who left the company last summer when Encorium sold its U.S. business to Pierrel Research USA and Ginsberg became CEO there. Ginsberg had replaced Lindevall as CEO in September 2008. Lindevall, who replaced Kenneth Borow, M.D., as CEO in February 2008, has served as executive chairman since Ginsberg became CEO. Board member Shahab Fatheazam will serve as Encorium’s new chairman.  

More... »

ICON to Create Translational Medicine Unit in UK

Monday, December 21, 2009 07:53 AM

Dublin-based contract research organization (CRO) ICON is preparing to open a new hospital-based translational medicine unit in the UK—the result of a partnership with the Central Manchester University Hospitals Foundation (CMFT).

More... »

ICON Founder to Retire as Board Chairman

Friday, December 18, 2009 07:23 AM

John Climax will retire as board chairman of Dublin-based contract research organization (CRO) ICON, effective December 31. Climax founded the company 19 years ago. He will remain as a board member, while Bruce Given steps into the role of chairman. Given, a healthcare products consultant, has served on ICON’s board for five years. Prior to becoming a consultant, he was president and CEO of Encysive Pharmaceuticals.

More... »

ICON Receives FDA Warning Letter

Wednesday, December 9, 2009 07:01 AM

Dublin contract research organization (CRO) ICON received a warning
letter from the U.S. Food and Drug Administration (FDA) related to the
management of two clinical studies conducted between 2004 and 2006.

More... »

ICON Extends Lilly Strategic Agreement to Japan

Thursday, November 12, 2009 07:45 AM

ICON has signed an extension to its strategic agreement with Eli Lilly and Company to manage the company’s clinical data management outside the U.S. This extension means that ICON will now also manage Lilly’s needs in Japan in addition to those in Europe, Canada, Latin America, Australia and Asia, which was originally agreed to in November 2008.

More... »